Black Diamond Therapeutics, Inc. (BDTX) Q1 2025 Earnings
BDTX·Reported May 12, 2025·Before market open
Black Diamond Therapeutics, Inc. reported Q1 2025 revenue of $70.0M, beat analyst consensus of $28.0M by $42.0M. Diluted EPS came in at $0.98, beat the $0.02 consensus by $0.96.
Revenue
$70.0Mbeat by $42.0M
Consensus: $28.0MDiluted EPS
$0.98beat by $0.96
Consensus: $0.02
Financial Snapshot
Trailing eight quarters through Q1 2025
Q1 2025 Earnings FAQ
Common questions about Black Diamond Therapeutics, Inc.'s Q1 2025 earnings report.
Black Diamond Therapeutics, Inc. (BDTX) reported Q1 2025 earnings on May 12, 2025 before market open.
Black Diamond Therapeutics, Inc. reported revenue of $70.0M and diluted EPS of $0.98 for Q1 2025.
Revenue beat the consensus estimate of $28.0M by $42.0M. EPS beat the consensus estimate of $0.02 by $0.96.
You can read the 10-Q periodic report (0001701541-25-000022) directly on SEC EDGAR. The filing index links above go to sec.gov.